カテゴリ： GlobalData, アメリカ, 企業調査

Abbott Laboratories (ABT)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Abbott Laboratories (ABT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8010841
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月20日
◆ページ数：176
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Abbott Laboratories (Abbott) is a healthcare company, which discovers, develops, manufactures, and sells a diversified range of healthcare products including drugs, diagnostics, branded generics, and vascular and nutritional products. The company’s products comprise specialized medicines; medical diagnostic instruments and tests; minimally invasive surgical devices; nutritional supplements for infants, children and adults; and products for veterinary care. It has research and development, manufacturing and administrative facilities across the world. The company markets its products in North America, Latin America, the Caribbean, the Middle East, Europe, Asia-Pacific and Africa. Abbott is headquartered in Abbott Park, Illinois, the US.

Abbott Laboratories (ABT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Abbott Laboratories, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Abbott Laboratories, Medical Devices Deals, 2011 to YTD 2017 13
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Abbott Laboratories, Pharmaceuticals & Healthcare, Deal Details 20
Asset Purchase 20
Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 20
Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For US$56.5 Million 22
Abbott Labs Acquires AP214 From Action Pharma For US$110 Million 24
Venture Financing 26
NeuroGenetic Pharma Raises US$0.2 Million In Venture Financing 26
NeuroGenetic Pharma Secures Investment In Venture Financing 27
AuraSense Therapeutics Secures Investment In Series B Financing 28
Creabilis Secures US$20 Million In Series B Financing 29
AM-Pharma Secures US$39.7 Million In Series D Financing 30
Spinal Modulation Secures US$30 Million In Series D Financing 32
Private Equity 34
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 34
Partnerships 36
BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs 36
Hennepin County Medical Center, University of Minnesota and Abbott Labs Enter into Agreement 37
AstraZeneca Enters into Co-Development Agreement with Abbott Labs 38
ALK-Abello Expands Partnership with Abbott Labs 39
Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 40
Abbott Labs Enters into Co-Development Agreement with US Department of Defense 41
Abbott Molecular Enters into Co-Development Agreement with Biocartis 42
Abbott Enters Into Distribution Agreement With WhanIn For Depakote 43
Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 44
ChemDiv Research Institute Expands Co-Development Agreement with Abbott Labs 45
biOasis Technologies Enters Into Research Agreement With Abbott Labs 46
Abbott India Enters Into Joint Venture Agreement With Syngene International 47
Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 48
DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 49
Abbott Labs Enters Into Co-Development Agreement With Yeda Research 50
Astellas Pharma Enters Into Distribution Agreement With Abbott Japan For Luvox 51
Abbott Labs Enters Into Co-Development Agreement With Biotest For BT-061 52
Seattle Genetics Enters Into Collaboration With Abbott 54
Partners In Health Forms Joint Venture With Abbott Labs And Abbott Fund 55
Licensing Agreements 56
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 56
Abbott India Enters into Licensing Agreement with Bharat Biotech 58
Abbott Molecular Enters into Licensing Agreement with Institut Curie 59
Sepstone Enters into Licensing Agreement with Abbott Labs 60
Zealand Pharma Enters Into Licensing Agreement With Abbott Labs For AP214 61
Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 62
Abbott Labs Enters Into Licensing Agreement With Pfizer 63
Lupin Enters Into Patent Licensing Agreement With Abbott For Antara 64
Equity Offering 65
Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares 65
Abbott Sells stock of Mylan for USD2.29 Billion 66
AbbVie Spin Out from Abbott Laboratories 67
CFR Pharma Completes IPO For US$373.3 Million 68
Debt Offering 69
Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 69
Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021 71
Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 73
Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 75
Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 77
Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 79
Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022 81
Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025 82
Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020 83
CFR International Completes Public Offering Of Notes For US$300 Million 84
Abbott Completes Private Placement Of Notes Due 2015 For US$500 Million 85
Abbott Completes Private Placement Of Notes Due 2015 For US$3.5 Billion 86
Abbott Completes Private Placement Of Notes Due 2017 For US$4 Billion 88
Abbott Completes Private Placement Of Notes Due 2042 For US$2.6 Billion 90
Abbott Completes Private Placement Of Notes Due 2018 For US$1 Billion 92
Abbott Completes Private Placement Of Notes Due 2022 For US$3.1 Billion 94
Abbott Labs Completes Private Placement Of Convertible Debt For US$0.1 Million 96
Asset Transactions 97
Abbott India May Sell Low-End Brands 97
Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 98
Zoetis Acquires Animal Health Assets of Abbott for USD255 Million 100
Abbott Labs Rumored To Divest Part Of Generic Drug Business 101
Acquisition 102
Abbott Labs Acquires Alere 102
Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 105
Abbott Labs Acquires CFR Pharma for USD2.9 Billion 106
Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 108
Abbott Labs to Acquire Veropharm from Roman Avdeev for up to USD496 Million 109
GardenHills Completes Acquisition Of Additional 29.09% Interest In Veropharm For US$86.3 Million 110
GardenHills To Acquire 47.99% Stake In Verofarm 112
Pfizer, Novartis And Abbott Labs Reportedly Plan To Bid For Ache Labs 113
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 115
CFR Pharma Acquires Laboratorio Franco Colombiano Lafrancol And Its Subsidiaries 117
AFK Sistema Plans To Acquire 51.8% Stake In Veropharm From Aptechnaya set’ 36,6 118
Russian Authorities Reject Abbott’s Bid To Acquire 62.5% Stake In Petrovax Pharm, Drug Manufacturer 119
CFR Pharma Acquires 50% Stake In Stellence For US$21 Million 121
STARLIMS Technologies Acquires Distribution Partners 122
CFR Pharma Acquires 41.88% Stake In Domesco Medical For US$14.4 Million 123
Chemo Group Acquires Remaining 50% Joint Venture Stake In Laboratorios Elea Mexico 124
Chemo Group Acquires Remaining 50% Joint Venture Stake In Servicios Elche 125
Chemo Group Acquires Remaining 50% Stake In Sinensix Pharma (Thailand) 126
CFR Pharma Acquires 50.79% Stake In Uman Pharma For US$26.5 Million 127
Gilead Sciences Acquires Arresto Biosciences 128
Abbott Laboratories – Key Competitors 130
Abbott Laboratories – Key Employees 131
Abbott Laboratories – Locations And Subsidiaries 133
Head Office 133
Other Locations & Subsidiaries 133
Recent Developments 151
Financial Announcements 151
Oct 18, 2017: Abbott Reports Third-Quarter 2017 Results 151
Jul 20, 2017: Abbott Reports Second-Quarter 2017 Results 154
Apr 19, 2017: Abbott Reports First-Quarter 2017 Results 156
Oct 19, 2016: Abbott Reports Third-Quarter 2016 Results 158
Jul 20, 2016: Abbott Reports Second-Quarter 2016 Results 161
Apr 20, 2016: Abbott Reports First-Quarter 2016 Results 164
Corporate Communications 167
Sep 22, 2017: Abbott and the Abbott Fund Provide $2 Million in Additional Relief to Help Families Affected by Hurricane Maria and the Earthquake in Central Mexico 167
Sep 18, 2017: Abbott and the Abbott Fund Expand Support for Hurricane Relief With $1 Million to Help Families Affected by Hurricane Irma 168
Aug 29, 2017: Abbott and the Abbott Fund Donate $1 Million to Support Hurricane Harvey Relief Efforts 169
Government and Public Interest 170
Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 170
Product News 171
Jul 18, 2016: Publication of HPTN 052 final results 171
Apr 07, 2016: Abbott Launches Eas Myoplex Sports Nutrition Line Designed For Performance 172
Mar 29, 2016: Abbott Introduces EnsureEnlive, Pairing the Latest in Science and Nutrition to Improve Health 173
Jan 18, 2016: Specialized nutrition supplement is associated with a 50 percent lower death rate in patients with heart or lung disease, new study shows 174
Appendix 176
Methodology 176
About GlobalData 176
Contact Us 176
Disclaimer 176

List of Tables
Abbott Laboratories, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Abbott Laboratories, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Abbott Laboratories, Deals By Therapy Area, 2011 to YTD 2017 11
Abbott Laboratories, Medical Devices Deals, 2011 to YTD 2017 13
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 20
Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For US$56.5 Million 22
Abbott Labs Acquires AP214 From Action Pharma For US$110 Million 24
NeuroGenetic Pharma Raises US$0.2 Million In Venture Financing 26
NeuroGenetic Pharma Secures Investment In Venture Financing 27
AuraSense Therapeutics Secures Investment In Series B Financing 28
Creabilis Secures US$20 Million In Series B Financing 29
AM-Pharma Secures US$39.7 Million In Series D Financing 30
Spinal Modulation Secures US$30 Million In Series D Financing 32
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 34
BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs 36
Hennepin County Medical Center, University of Minnesota and Abbott Labs Enter into Agreement 37
AstraZeneca Enters into Co-Development Agreement with Abbott Labs 38
ALK-Abello Expands Partnership with Abbott Labs 39
Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 40
Abbott Labs Enters into Co-Development Agreement with US Department of Defense 41
Abbott Molecular Enters into Co-Development Agreement with Biocartis 42
Abbott Enters Into Distribution Agreement With WhanIn For Depakote 43
Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 44
ChemDiv Research Institute Expands Co-Development Agreement with Abbott Labs 45
biOasis Technologies Enters Into Research Agreement With Abbott Labs 46
Abbott India Enters Into Joint Venture Agreement With Syngene International 47
Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 48
DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 49
Abbott Labs Enters Into Co-Development Agreement With Yeda Research 50
Astellas Pharma Enters Into Distribution Agreement With Abbott Japan For Luvox 51
Abbott Labs Enters Into Co-Development Agreement With Biotest For BT-061 52
Seattle Genetics Enters Into Collaboration With Abbott 54
Partners In Health Forms Joint Venture With Abbott Labs And Abbott Fund 55
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 56
Abbott India Enters into Licensing Agreement with Bharat Biotech 58
Abbott Molecular Enters into Licensing Agreement with Institut Curie 59
Sepstone Enters into Licensing Agreement with Abbott Labs 60
Zealand Pharma Enters Into Licensing Agreement With Abbott Labs For AP214 61
Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 62
Abbott Labs Enters Into Licensing Agreement With Pfizer 63
Lupin Enters Into Patent Licensing Agreement With Abbott For Antara 64
Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares 65
Abbott Sells stock of Mylan for USD2.29 Billion 66
AbbVie Spin Out from Abbott Laboratories 67
CFR Pharma Completes IPO For US$373.3 Million 68
Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 69
Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021 71
Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 73
Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 75
Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 77
Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 79
Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022 81
Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025 82
Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020 83
CFR International Completes Public Offering Of Notes For US$300 Million 84
Abbott Completes Private Placement Of Notes Due 2015 For US$500 Million 85
Abbott Completes Private Placement Of Notes Due 2015 For US$3.5 Billion 86
Abbott Completes Private Placement Of Notes Due 2017 For US$4 Billion 88
Abbott Completes Private Placement Of Notes Due 2042 For US$2.6 Billion 90
Abbott Completes Private Placement Of Notes Due 2018 For US$1 Billion 92
Abbott Completes Private Placement Of Notes Due 2022 For US$3.1 Billion 94
Abbott Labs Completes Private Placement Of Convertible Debt For US$0.1 Million 96
Abbott India May Sell Low-End Brands 97
Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 98
Zoetis Acquires Animal Health Assets of Abbott for USD255 Million 100
Abbott Labs Rumored To Divest Part Of Generic Drug Business 101
Abbott Labs Acquires Alere 102
Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 105
Abbott Labs Acquires CFR Pharma for USD2.9 Billion 106
Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 108
Abbott Labs to Acquire Veropharm from Roman Avdeev for up to USD496 Million 109
GardenHills Completes Acquisition Of Additional 29.09% Interest In Veropharm For US$86.3 Million 110
GardenHills To Acquire 47.99% Stake In Verofarm 112
Pfizer, Novartis And Abbott Labs Reportedly Plan To Bid For Ache Labs 113
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 115
CFR Pharma Acquires Laboratorio Franco Colombiano Lafrancol And Its Subsidiaries 117
AFK Sistema Plans To Acquire 51.8% Stake In Veropharm From Aptechnaya set' 36,6 118
Russian Authorities Reject Abbott's Bid To Acquire 62.5% Stake In Petrovax Pharm, Drug Manufacturer 119
CFR Pharma Acquires 50% Stake In Stellence For US$21 Million 121
STARLIMS Technologies Acquires Distribution Partners 122
CFR Pharma Acquires 41.88% Stake In Domesco Medical For US$14.4 Million 123
Chemo Group Acquires Remaining 50% Joint Venture Stake In Laboratorios Elea Mexico 124
Chemo Group Acquires Remaining 50% Joint Venture Stake In Servicios Elche 125
Chemo Group Acquires Remaining 50% Stake In Sinensix Pharma (Thailand) 126
CFR Pharma Acquires 50.79% Stake In Uman Pharma For US$26.5 Million 127
Gilead Sciences Acquires Arresto Biosciences 128
Abbott Laboratories, Key Competitors 130
Abbott Laboratories, Key Employees 131
Abbott Laboratories, Other Locations 133
Abbott Laboratories, Subsidiaries 133

★海外企業調査レポート[Abbott Laboratories (ABT)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Aspect Imaging Inc：医療機器：M&Aディール及び事業提携情報
    Summary Aspect Imaging Inc (Aspect Imaging) is a medical device company that develops and manufactures magnetic resonance imaging systems. The company’s products comprise wristview medical systems, preclinical, process control, oil and gas analyzers, NMR, materials MRI and software. It offers precli …
  • Life Time Inc：企業の戦略的SWOT分析
    Life Time Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Torraspapel, S.A.：企業の戦略的SWOT分析
    Torraspapel, S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Innate Pharma SA (IPH)：企業の財務・戦略的SWOT分析
    Summary Innate Pharma SA (Innate Pharma) is a healthcare products provider that develops immunopharmacology and antibody technology products. The company carries out the discovery and development of therapeutic antibodies for the treatment of cancer and inflammatory diseases. It develops new monoclo …
  • Novotech (Australia) Pty Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Novotech (Australia) Pty Ltd (Novotech) is a contract research organization that offers clinical development services. The organization’s services include clinical trials, data management, biostatistics analysis, audits, regulatory affairs, medical writing, site management and commercializat …
  • Lexmark International Inc：医療機器：M&Aディール及び事業提携情報
    Summary Lexmark International Inc (Lexmark) a subsidiary of Ninestar Corp., provider of imaging and printing solutions. It manufactures, develops and supplies printing and imaging solutions, managed print services, device management, document workflow, business process and content management solutio …
  • Japan Petroleum Exploration Co Ltd (1662)：企業の財務・戦略的SWOT分析
    Japan Petroleum Exploration Co Ltd (1662) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Cesca Therapeutics Inc (KOOL)：製品パイプライン分析
    Summary Cesca Therapeutics Inc (Cesca) researches, develops, and commercializes cell based therapeutics for applications in regenerative medicine. Its proprietary technology platform, PXP is used to develop autologous cell-based therapies for the in the vascular and orthopedic markets. Its device di …
  • Sihuan Pharmaceutical Holdings Group Ltd (460)：製薬・医療：M&Aディール及び事業提携情報
    Summary Sihuan Pharmaceutical Holdings Group Ltd (Sihuan Pharmaceutical) is a pharmaceutical company that develops, manufactures and markets prescription drugs. The company offers products in the therapeutic areas of cardio-cerebral vascular system, central nervous system, metabolism, oncology and a …
  • TAG Oil Ltd (TAO)：石油・ガス：M&Aディール及び事業提携情報
    Summary TAG Oil Ltd (TAG Oil) is an oil and gas company that explores, develops and produces natural gas and crude oil across Canada. The company owns and operates oil and gas properties in Taranaki Basin and East Coast Basin. It undertakes oil and gas projects such as Boar Hill Frontier, Waitangi H …
  • AltaGas Ltd (ALA)-石油・ガス分野：企業M&A・提携分析
    Summary AltaGas Ltd. (AltaGas), is an energy utility. The company undertakes activities related to extraction, transmission, distribution and storage of natural gas. AltaGas generates electricity utilizing diverse fuel sources, such as wind, run-of-river hydro, geothermal and gas-fired generation pl …
  • DBV Technologies SA (DBV)：企業の財務・戦略的SWOT分析
    Summary DBV Technologies SA (DBV) is a biopharmaceutical company that develops products for the diagnosis and treatment of food and pediatric allergies. The company develops and markets non-invasive epicutaneous delivery technology and products for healthcare markets. Its viaskin technology platform …
  • Biom’Up SAS (BUP)：医療機器：M&Aディール及び事業提携情報
    Summary Biom'Up SAS (Biom'Up) is a medical device company that designs, develops and manufactures collagen-based absorbable medical devices for biosurgery. The company's products include covamesh, hemosnow, hemoblast bellows, cova and matri bone, among others. It offers collagens, resorbable polymer …
  • Wistron Corporation
    Wistron Corporation - Strategy, SWOT and Corporate Finance Report Summary Wistron Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Petroleos Mexicanos：企業の戦略的SWOT分析
    Petroleos Mexicanos - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • The Hain Celestial Group, Inc.：企業の戦略・SWOT・財務情報
    The Hain Celestial Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Hain Celestial Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Mobidiag Ltd：医療機器：M&Aディール及び事業提携情報
    Summary Mobidiag Ltd (Mobidiag) is a biotechnology company that develops and markets products for molecular diagnosis of infectious diseases and test kits. The company's products include Novodiag, Amplidiag, and Prove-it. Its Amplidiag is a diagnostic test for high-volume screening of gastrointestin …
  • UGI Corp (UGI)：企業の財務・戦略的SWOT分析
    UGI Corp (UGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Brown & Brown, Inc.：企業のM&A・事業提携・投資動向
    Brown & Brown, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Brown & Brown, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Petroleos Mexicanos-石油・ガス分野：企業M&A・提携分析
    Summary Petroleos Mexicanos (PEMEX) is a state owned vertically integrated oil and gas company. The company explores for, develops and produces crude oil and natural gas. It also refines and markets petroleum products. PEMEX gathers and processes natural gas products. It manufactures and markets a w …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆